| abstract |
Compounds of formula (I), their stable salts and pharmaceutically acceptable derived esters, as well as processes for their preparation, where: R1 is pyridyl, pyrrolyl, imidazolyl, thiazolyl, thiazolinyl or oxazolyl, optionally substituted with halogen, lower alkyl, hydroxy-alkyl -lower or lower alkenyl; R2 is R21 (where R1 is cyano, hydroxy-lower-alkyl, carboxy, among others), -O-R22-, -N-R22 (where R22 is hydrogen, lower alkanoyl, lower carboxyalkyl, lower alkoxycarbonyl, among others) or heterocyclyl, which may be optionally mono-, di-, or tri-substituted independently; X is -CH- or -N-. Examples of selected compounds of formula (I): 4- [4-Methoxy-5- (2-methoxy-phenoxy) -6- (5-methyl-pyridin-2-sulfonylamino) -pyrimidin-2-yl] -pyridin -2-carboxylic; 4- [4-Methoxy-5- (2-methoxy-phenoxy) -6- (5-methyl-pyridin-2-sulfonylamino) -pyrimidin-2-yl] -pyridin-2-carboxylic acid methyl ester; 5-Methyl-pyridin-2-sulfonic acid [2- (2-hydroxymethyl-pyridin-4-yl) -6-methoxy-5- (2-methoxy-phenoxy) -pyrimidin-4-yl] -amide; among others. These compounds are endothelin receptor inhibitors and can therefore be used for the treatment of disorders that are associated with abnormal vascular tone and endothelial dysfunction. SEE CLAIMS |